Vical grants additional academic licenses for core technology

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Vical, Inc. has granted non-exclusive, academic licenses for its broad DNA delivery technology patent estate to six additional research institutions - Fred Hutchinson Cancer Research Center, Texas Tech University Health Sciences Center, University of Iowa, University of Notre Dame, University of Pittsburgh and University of Washington.

Earlier this year, the company announced the grant of academic licenses on the same terms to Stanford University, Harvard University, Yale University and the Massachusetts Institute of Technology.

The San Diego biopharmaceutical company said the academic licenses are intended to encourage widespread commercial use of the company's DNA-delivery technologies in the development of new antibodies, vaccines, therapeutic proteins and diagnostics.

The nonexclusive academic licenses allow university researchers to use Vical's technology free of charge for educational and internal, non-commercial research purposes. In exchange, Vical said it will have the option to exclusively license from the universities potential commercial applications stemming from the technology on terms to be negotiated.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.